TapewireFind a company

person · Reporting owner

Fridriksdottir Hafrun

Disclosed activity across 1 company

Tapewire entity
127160
SEC CIK
0001561458

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063Executive VP, Global R&DMay 17, 2022May 19, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TEVA PHARMACEUTICAL INDUSTRIES LTD

Report date May 17, 2022 · Filed May 19, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect1,386.514 Reported balance After 2022-05-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2022-05-17 · Sale · Disposed 130,000 · Balance 1,386.514

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.

Filing footnotes · ownership attribution and instrument terms

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 17, 2022 Filed May 19, 2022 11:31 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 130,000 $8.22 $1,068,067.00
Disclosure

SEC source: 0001209191-22-030308 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,386.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.185 to $8.240, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3 · balance_after: The shares held by the reporting person prior to the sale reported in this Form 4 included 5,300 Ordinary Shares previously issued to the reporting person in exempt transactions in connection with the settlement of certain equity-based awards granted to the reporting person, which were inadvertently omitted from the reporting person's previously reported amount of securities beneficially owned.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 8,941 $7.37 $65,865.66
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 126,086.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.49, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 23,764 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 10

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,293

Underlying: Ordinary Shares · 23,764 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F10 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.

F10 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 having vested on March 5, 2022, 23,764 vesting on each of March 5, 2023 and March 5, 2024, and 23,765 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 05, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 23,764 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,027.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 140,750 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 9

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,750

Underlying: Ordinary Shares · 140,750 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F9 · derivative.exercise_date: Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189 vesting on March 4, 2026.

F9 · derivative.expiration_date: Restricted share units were granted on March 4, 2022, with 35,187 vesting on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 35,189 vesting on March 4, 2026.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 18,905 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 8

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,906

Underlying: Ordinary Shares · 18,905 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023.

F8 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 having vested on each of March 4, 2021 and March 4, 2022, and 18,906 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 51,488 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · derivative · entry 7

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 51,488 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F7 · derivative.expiration_date: Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,618 $7.48 $49,519.19
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,263.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 18,905 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,881.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 18,020 $7.48 $134,834.65
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,976.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.60, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2022 Filed Mar 8, 2022 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 51,488 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-017046 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 116,996.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:47 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,682 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-014469 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,366

Underlying: Ordinary Shares · 21,682 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020, with 21,682 having vested on each of February 28, 2021 and February 28, 2022, 21,682 vesting on February 28, 2023 and 21,684 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:47 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 7,590 $8.14 $61,799.30
Disclosure

SEC source: 0001209191-22-014469 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,508.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2022 Filed Mar 2, 2022 12:47 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,682 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-014469 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,098.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 16,121 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008415 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 16,121 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022.

F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 having vested on each of February 9, 2020 and February 9, 2021 and 16,121 having vested on February 9, 2022.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 6,116 $9.06 $55,412.18
Disclosure

SEC source: 0001209191-22-008415 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,416.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2022 Filed Feb 10, 2022 21:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 16,121 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-008415 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,532.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 08, 2022 Filed Feb 10, 2022 21:09 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 51,488 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-008415 · doc4.xml · derivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,488

Underlying: Ordinary Shares · 51,488 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

F7 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022.

Read SEC document
August 10, 2021 Filed Aug 12, 2021 20:04 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 50,860 $9.95 $506,021.40
Disclosure

SEC source: 0001209191-21-051075 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,411.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.91 to $10.00, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 11, 2021 Filed May 13, 2021 11:45 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 37,884 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-032252 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 37,884 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on February 9, 2021 pursuant to the satisfaction of performance criteria and vested on May 11, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
May 11, 2021 Filed May 13, 2021 11:45 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 19,066 $10.22 $194,829.73
Disclosure

SEC source: 0001209191-21-032252 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,271.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.205 to $10.230, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
May 11, 2021 Filed May 13, 2021 11:45 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 37,884 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-032252 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,337.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 05, 2021 Filed Mar 8, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 95,057 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018518 · doc4.xml · derivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,057

Underlying: Ordinary Shares · 95,057 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025.

F7 · derivative.expiration_date: Restricted share units were granted on March 5, 2021, with 23,764 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 23,765 vesting on March 5, 2025.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 18,905 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-018518 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,811

Underlying: Ordinary Shares · 18,905 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.

F6 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 18,905 vesting on each of March 4, 2021 and March 4, 2022 and 18,906 vesting on March 4, 2023.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 9,515 $10.57 $100,536.44
Disclosure

SEC source: 0001209191-21-018518 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,453.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.510 to $10.690, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 04, 2021 Filed Mar 8, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 18,905 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-018518 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,968.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 02, 2021 Filed Mar 4, 2021 21:03 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 50,000 $10.82 $540,890.00
Disclosure

SEC source: 0001209191-21-017758 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,063.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.790 to $10.870, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 01, 2021 Filed Mar 2, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 10,912 $10.83 $118,185.69
Disclosure

SEC source: 0001209191-21-015842 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 114,063.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.78 to $11.01, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 21,682 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-015842 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,048

Underlying: Ordinary Shares · 21,682 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024.

F6 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 28, 2021 Filed Mar 2, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 21,682 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-015842 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,975.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 16, 2021 Filed Feb 17, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 2,098 $11.12 $23,335.84
Disclosure

SEC source: 0001209191-21-011244 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,293.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.105 to $11.135, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 14, 2021 Filed Feb 17, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,355 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-011244 · doc4.xml · derivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,355 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2021 Filed Feb 17, 2021 21:07 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 5,355 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-011244 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,391.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 37,884 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,884

Underlying: Ordinary Shares · 37,884 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F9 · derivative.exercise_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021.

F9 · derivative.expiration_date: Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on May 11, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 16,120 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,121

Underlying: Ordinary Shares · 16,120 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F8 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F8 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 16,120 vesting on each of February 9, 2020 and February 9, 2021 and 16,121 vesting on February 9, 2022.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 23,639 $12.69 $300,085.29
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,036.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 5,857 $12.69 $74,351.69
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 123,675.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F5 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F6 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.635 to $12.785, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantOrdinary Shares 67,852 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,532.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: Represents ordinary shares received upon satisfaction of performance- and time-based vesting criteria of performance share units.

F4 · price: Each performance share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 09, 2021 Filed Feb 11, 2021 21:05 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 16,120 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-21-009633 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,680.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 266 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 266 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F7 · derivative.expiration_date: Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 748 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 748 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F6 · derivative.expiration_date: Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 134 $7.16 $959.91
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,560.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 380 $7.16 $2,722.13
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,694.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.1600 to $7.1850, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 266 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 2

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,074.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
March 17, 2020 Filed Mar 19, 2020 11:33 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionOrdinary Shares 748 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-020163 · doc4.xml · nonDerivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,808.514

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 12:11 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 GrantRestricted Share Units · Derivative 86,730 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-014849 · doc4.xml · derivative · entry 1

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,730

Underlying: Ordinary Shares · 86,730 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F2 · derivative.exercise_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024.

F2 · derivative.expiration_date: Restricted share units were granted on February 28, 2020 with 21,682 vesting on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 21,684 vesting on February 28, 2024.

F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 17,850 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · derivative · entry 6

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 17,850 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F7 · derivative.exercise_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020.

F7 · derivative.expiration_date: Restricted share units were granted on February 11, 2020 pursuant to the satisfaction of performance criteria and vested on February 14, 2020.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 Exercise / conversionRestricted Share Units · Derivative 5,353 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · derivative · entry 5

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,355

Underlying: Ordinary Shares · 5,353 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

F6 · derivative.exercise_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F6 · derivative.expiration_date: Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Read SEC document
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 8,825 $12.14 $107,154.92
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 4

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,060.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document
February 14, 2020 Filed Feb 18, 2020 12:23 UTC TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 SaleOrdinary Shares 2,647 $12.14 $32,140.40
Disclosure

SEC source: 0001209191-20-009879 · doc4.xml · nonDerivative · entry 3

Fridriksdottir Hafrun · CIK 0001561458 · Executive VP, Global R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,885.514

F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

F3 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.962 to $12.2800, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.